Skip to main content

Parliamentary debates and questions

S5W-19373: Alex Cole-Hamilton (Edinburgh Western)

Scottish Liberal Democrats

Date lodged: 11 October 2018

To ask the Scottish Government when the tumour profiling test for breast cancer patients, Oncotype DX, was made available for use by the NHS; which NHS boards offer this, and what information it has regarding the frequency of its use.

Answered by: Jeane Freeman 8 November 2018

NHS Boards are responsible for providing services to meet the assessed needs of their resident populations, taking into account relevant frameworks and guidance and within their annual allocations. Limited data on the provision and frequency of Oncotype DX is held by Scottish Government, which is summarised in the following table.

Oncotype DX provision and frequency information by NHS Board held by Scottish Government

NHS Board

Date from which Oncotype DX was made available

Frequency of use

NHS Lothian

Unknown

33 patients up to end of 2017

NHS Fife

Since early 2017

Approximately 16 patients

NHS Borders

Unknown

No patients tested since it became available. This is due to patients who have met the criteria declining the test

NHS Dumfries and Galloway

From approximately 2015-2016

Unknown

NHS Greater Glasgow and Clyde

1 st April 2016

An average of 13 tests a month across all four west of Scotland health boards.

A total of 409 tests between April 2016 and September 2018.

NHS Forth Valley

1 st April 2016

NHS Lanarkshire

1 st April 2016

NHS Ayrshire and Arran

1 st April 2016